WO2008136392A1 - 経口投与用製剤 - Google Patents

経口投与用製剤 Download PDF

Info

Publication number
WO2008136392A1
WO2008136392A1 PCT/JP2008/058036 JP2008058036W WO2008136392A1 WO 2008136392 A1 WO2008136392 A1 WO 2008136392A1 JP 2008058036 W JP2008058036 W JP 2008058036W WO 2008136392 A1 WO2008136392 A1 WO 2008136392A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
oral administration
disclosed
disintegrant
diabetes
Prior art date
Application number
PCT/JP2008/058036
Other languages
English (en)
French (fr)
Inventor
Wataru Wakui
Jun Kosaka
Takashi Fukutani
Masatomo Mizuno
Original Assignee
Ajinomoto Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2007/059544 external-priority patent/WO2008139575A1/ja
Priority claimed from PCT/JP2007/059545 external-priority patent/WO2008139576A1/ja
Priority claimed from PCT/JP2007/059540 external-priority patent/WO2008139574A1/ja
Application filed by Ajinomoto Co., Inc. filed Critical Ajinomoto Co., Inc.
Publication of WO2008136392A1 publication Critical patent/WO2008136392A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

　本発明は、糖尿病治療に有用な経口投与用製剤を提供することを課題とする。本発明は、特定構造を有するラクタム化合物またはその製薬学的に許容される塩を有効成分として含有し、さらに少なくとも１種の崩壊剤を含有する経口投与用製剤を提供することにより上記課題を解決する。
PCT/JP2008/058036 2007-04-27 2008-04-25 経口投与用製剤 WO2008136392A1 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/JP2007/059544 WO2008139575A1 (ja) 2007-04-27 2007-04-27 経口投与用製剤
JPPCT/JP2007/059545 2007-04-27
PCT/JP2007/059545 WO2008139576A1 (ja) 2007-04-27 2007-04-27 ラクタム化合物の製造方法及びその製造中間体
PCT/JP2007/059540 WO2008139574A1 (ja) 2007-04-27 2007-04-27 ラクタム化合物の結晶形およびその製造方法
JPPCT/JP2007/059540 2007-04-27
JPPCT/JP2007/059544 2007-04-27

Publications (1)

Publication Number Publication Date
WO2008136392A1 true WO2008136392A1 (ja) 2008-11-13

Family

ID=39943501

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/JP2008/058038 WO2008136394A1 (ja) 2007-04-27 2008-04-25 ラクタム化合物の製造方法及びその製造中間体
PCT/JP2008/058037 WO2008136393A1 (ja) 2007-04-27 2008-04-25 ラクタム化合物の結晶形およびその製造方法
PCT/JP2008/058036 WO2008136392A1 (ja) 2007-04-27 2008-04-25 経口投与用製剤

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/JP2008/058038 WO2008136394A1 (ja) 2007-04-27 2008-04-25 ラクタム化合物の製造方法及びその製造中間体
PCT/JP2008/058037 WO2008136393A1 (ja) 2007-04-27 2008-04-25 ラクタム化合物の結晶形およびその製造方法

Country Status (1)

Country Link
WO (3) WO2008136394A1 (ja)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011161030A1 (de) 2010-06-21 2011-12-29 Sanofi Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren
WO2012004270A1 (de) 2010-07-05 2012-01-12 Sanofi Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012004269A1 (de) 2010-07-05 2012-01-12 Sanofi ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012010413A1 (de) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2016104441A1 (ja) * 2014-12-22 2016-06-30 Ｅａファーマ株式会社 角膜上皮障害治療剤
JP2016147866A (ja) * 2010-05-11 2016-08-18 ヤンセン ファーマシューティカ エヌ．ベー． ＳＧＬＴの阻害剤としての１−（β−Ｄ−グルコピラノシル）−２−チエニル−メチルベンゼン誘導体を含有する医薬製剤
JP2016183188A (ja) * 2016-07-11 2016-10-20 ニプロ株式会社 口腔内崩壊錠
US11576894B2 (en) 2009-07-08 2023-02-14 Janssen Pharmaceutica Nv Combination therapy for the treatment of diabetes

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012180283A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
JP2012180282A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526227A (ja) * 1997-12-22 2001-12-18 シェーリング コーポレイション バイオアベイラビリティーを高めた分子分散組成物
WO2004069259A1 (ja) * 2003-02-07 2004-08-19 Ajinomoto Co., Inc. 糖尿病治療剤
WO2005013964A1 (ja) * 2003-08-08 2005-02-17 Ajinomoto Co., Inc. ナテグリニド含有製剤
WO2006132440A1 (ja) * 2005-06-09 2006-12-14 Takeda Pharmaceutical Company Limited 固形製剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4327424B2 (ja) * 2000-05-15 2009-09-09 武田薬品工業株式会社 結晶の製造法
EP1346993B1 (en) * 2000-12-01 2009-10-21 Ajinomoto Co., Inc. Lactam compounds and medical use thereof
ITMI20011727A1 (it) * 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Solvati della lercanidipina cloridrato e nuove forme cristalline della lercanidipina cloridrato ottenute da essi
WO2005042536A1 (ja) * 2003-10-31 2005-05-12 Ajinomoto Co., Inc. 複素環を有する新規縮合多環式化合物及びその医薬用途
TW200616634A (en) * 2004-10-01 2006-06-01 Bristol Myers Squibb Co Crystalline forms and process for preparing spiro-hydantoin compounds
EP1878734A4 (en) * 2005-04-28 2010-02-17 Ajinomoto Kk NEW COMPOUND LACTAME

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526227A (ja) * 1997-12-22 2001-12-18 シェーリング コーポレイション バイオアベイラビリティーを高めた分子分散組成物
WO2004069259A1 (ja) * 2003-02-07 2004-08-19 Ajinomoto Co., Inc. 糖尿病治療剤
WO2005013964A1 (ja) * 2003-08-08 2005-02-17 Ajinomoto Co., Inc. ナテグリニド含有製剤
WO2006132440A1 (ja) * 2005-06-09 2006-12-14 Takeda Pharmaceutical Company Limited 固形製剤

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11576894B2 (en) 2009-07-08 2023-02-14 Janssen Pharmaceutica Nv Combination therapy for the treatment of diabetes
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2016147866A (ja) * 2010-05-11 2016-08-18 ヤンセン ファーマシューティカ エヌ．ベー． ＳＧＬＴの阻害剤としての１−（β−Ｄ−グルコピラノシル）−２−チエニル−メチルベンゼン誘導体を含有する医薬製剤
US10617668B2 (en) 2010-05-11 2020-04-14 Janssen Pharmaceutica Nv Pharmaceutical formulations
WO2011161030A1 (de) 2010-06-21 2011-12-29 Sanofi Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren
WO2012004269A1 (de) 2010-07-05 2012-01-12 Sanofi ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012010413A1 (de) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012004270A1 (de) 2010-07-05 2012-01-12 Sanofi Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2016104441A1 (ja) * 2014-12-22 2016-06-30 Ｅａファーマ株式会社 角膜上皮障害治療剤
CN107106572A (zh) * 2014-12-22 2017-08-29 Ea制药株式会社 角膜上皮障碍治疗剂
JPWO2016104441A1 (ja) * 2014-12-22 2017-10-05 Ｅａファーマ株式会社 角膜上皮障害治療剤
JP2016183188A (ja) * 2016-07-11 2016-10-20 ニプロ株式会社 口腔内崩壊錠

Also Published As

Publication number Publication date
WO2008136393A1 (ja) 2008-11-13
WO2008136394A1 (ja) 2008-11-13

Similar Documents

Publication Publication Date Title
WO2008136392A1 (ja) 経口投与用製剤
WO2009017837A3 (en) Sublingual fentanyl spray
WO2007087548A3 (en) Chemical compounds
WO2009051119A1 (ja) ピリミジルインドリン化合物
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2007135529A3 (en) Azabenzimidazolyl compounds as mglur2 potentiators
ZA200706021B (en) 1-thio-D-glucitol derivatives
GEP20084468B (en) Gamma-d crystalline form of ivabradin hydrochloride, process for its preparation and pharmaceutical compositions containing it
WO2008096001A8 (en) Hcv inhibiting macrocyclic phenylcarbamates
WO2009115178A3 (de) Gingival-wafer
WO2005044192A3 (en) Triazole compounds and uses related thereto
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2007095039A3 (en) Pharmaceutical formulations
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
WO2010070449A3 (en) Highly pure laquinimod or a pharmaceutically acceptable salt thereof
WO2009060952A1 (ja) 新規製剤
WO2007145863A3 (en) Sustained release formulation of naltrexone
EP2316420A8 (en) Method to reduce pain
WO2004098594A3 (en) Dosage form containing pantoprazole as active ingredient
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
WO2008094912A3 (en) Substituted gamma lactams as therapeutic agents
WO2007133481A3 (en) Method for increasing the bioavailability of benzhydryl piperazine containing compounds
WO2004098577A3 (en) Dosage form containing (s)-pantoprazole as active ingredient
WO2010013925A3 (en) Pharmacological composition for prevention and treatment of respiratory disease containing pyrazolopyrimidinone compound or pharmaceutically acceptable salts thereof
WO2009096667A3 (ko) 신규한 퀴나졸린-2,4-디온 유도체 및 이를 함유하는 뇌신경질환 예방 및 치료용 의약 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08752110

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 08752110

Country of ref document: EP

Kind code of ref document: A1